TL;DR: Tirzepatide is a dual GIP/GLP-1 agonist with established phase-3 data showing ~22.5% mean body-weight reduction at 72 weeks. Retatrutide is a triple GIP/GLP-1/glucagon agonist trending toward ~24.2% loss in phase-2 (TRIUMPH-1) — more aggressive efficacy, less long-term data. For most Philippine customers starting today, Tirzepatide remains the safer, evidence-rich choice; Retatrutide is for those willing to ride the leading edge.
TL;DR — quick comparison table
| Dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + Glucagon (triple agonist) |
| Peak weight loss (trial) | ~22.5% at 72 weeks (SURMOUNT-1) | ~24.2% at 48 weeks (TRIUMPH-1, phase 2) |
| Trial stage | Phase 3 complete; FDA-approved active molecule | Phase 3 ongoing (TRIUMPH program) |
| Typical reference dose | 2.5 mg week, titrate to 15 mg weekly | 2 mg week, titrate to 12 mg weekly |
| Common side effects | Nausea, mild GI, decreased appetite | Nausea, GI, transient HR increase, sweating |
| PH availability | Widely available via reputable suppliers | Limited; few verified suppliers |
| Noki Labs price | ₱2,000–₱3,500 across 4 variants | ₱2,500–₱3,200 across 2 variants |
| Best for | First-time GLP-1 users, steady protocols | Individuals prioritising peak efficacy, advanced protocols |
How each peptide works (the science)
Tirzepatide: dual incretin mechanism
Tirzepatide is a synthetic, once-weekly dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. By engaging both incretin pathways at the same time, it amplifies post-prandial insulin response, slows gastric emptying, and meaningfully reduces appetite signaling in the hypothalamus. The dual mechanism is what enabled it to outperform pure GLP-1 monotherapy in head-to-head SURPASS-2 data.
For Philippine customers, the molecule's well-mapped pharmacokinetic profile (half-life ~5 days) makes once-weekly dosing intuitive and reproducible. Tirzepatide's identity as a GIP/GLP-1 dual agonist is also why it produces less GI burden per kg of weight loss than older single-agonist incretins.
Retatrutide: triple agonist with glucagon recruitment
Retatrutide adds a third receptor — glucagon — to the GIP/GLP-1 platform. Glucagon agonism is a counter-intuitive addition: glucagon classically raises blood sugar, but in this context it drives hepatic energy expenditure and lipolysis, increasing total caloric burn while the GIP/GLP-1 components still suppress appetite and stabilize glucose.
The result in TRIUMPH-1 (Jastreboff et al., NEJM 2023) was the steepest weight-loss curve documented for any peptide-based compound at the 48-week mark. The trade-off is a slightly higher rate of transient heart-rate elevation and a less mature long-term safety database.
Clinical evidence — head to head
Tirzepatide: SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported mean body-weight reduction of 15.0%, 19.5%, and 20.9% at 5 mg, 10 mg, and 15 mg respectively over 72 weeks, with a placebo-adjusted figure approaching 22.5%. SURPASS-2 demonstrated superiority over semaglutide 1 mg in head-to-head glycaemic and weight outcomes.
Retatrutide: TRIUMPH-1 (NEJM 2023) reported mean placebo-adjusted weight reduction of 24.2% at the 12 mg dose by week 48. Continued follow-up at week 88 in the Lancet Diabetes & Endocrinology supplementary analysis suggested loss continuing past 25%.
The honest read: Retatrutide's curve is steeper, but the n is smaller and the follow-up shorter. For an individual prioritising replicated, multi-site phase-3 data, Tirzepatide wins. For an individual modeling maximum theoretical efficacy, Retatrutide leads.
Cost in the Philippines
Pricing is one of the most under-discussed variables. A typical 12-week titrated reference protocol consumes roughly 60 mg of either compound. Compare a market reference like Atlas Compounds (~₱7,899/vial Retatrutide) and MedsGo (~₱5,985/vial Tirzepatide) against Noki Labs:
| Compound | Noki Labs PH | Reference market | 12-week cost (Noki) |
|---|---|---|---|
| Tirzepatide 10 mg | ~₱2,800 | ₱5,985 | ~₱16,800 |
| Retatrutide 10 mg | ~₱2,900 | ₱7,899 | ~₱17,400 |
Noki Labs is ~50–60% below the comparable Philippine reference market. Apply WELCOME10 for first-order 10% off, or BULK20 for orders over ₱15,000.
Side effects — what's different
Both share the GLP-1 family signature: nausea, mild abdominal discomfort, occasional reflux, decreased appetite. Retatrutide adds two distinct signals — a small, dose-dependent rise in resting heart rate (~3–7 bpm) and slightly higher rates of transient sweating and warmth — both attributed to the glucagon component's effect on energy expenditure. Tirzepatide's GI profile is generally judged milder per percentage of weight lost.
Which is better for [persona/goal]?
If you're new to GLP-1 peptides
Start with Tirzepatide. The dosing literature is denser, side-effects are well-mapped, and titration is forgiving. Pair it with our Tirzepatide Philippines guide for protocol detail.
If you want maximum weight loss
Retatrutide. The TRIUMPH curve is the steepest in the modern peptide literature. Read the Retatrutide Philippines pillar before ordering.
If you have GI sensitivity
Tirzepatide, paired with a slow titration (start 2.5 mg, hold 4 weeks). Or consider stacking with Cagrilintide for amylin-mediated appetite control with less GI hit.
Stacking Tirzepatide with Retatrutide
Direct co-administration of two incretin agonists is not standard and is not recommended in current literature. The more evidence-based stack is Tirzepatide + Cagrilintide — the so-called "CagriSema-class" approach. We cover it in detail in our Tirzepatide + Cagrilintide Stack guide.
Where to buy in the Philippines
Both peptides are stocked at Noki Labs PH with verified third-party COAs. Browse the weight-management collection or jump direct:
- Tirzepatide: /products/tirzepatide — 4 variants, ₱2,000–₱3,500
- Retatrutide: /products/retatrutide — 2 variants, ₱2,500–₱3,200
Manila-based customers can read shipping detail on /pages/peptide-supplier-manila.
FAQ
Q: Is Retatrutide stronger than Tirzepatide? In phase-2 head-to-head modeling, yes — ~24.2% vs ~22.5% at peak dose. But Tirzepatide has more replicated long-term data.
Q: Can I switch from Tirzepatide to Retatrutide? Individuals on titrated protocols typically wash out 1–2 weeks before switching, then re-titrate from a low Retatrutide starting dose.
Q: Which has worse nausea? Per-mg, similar. Per-percentage of weight lost, Tirzepatide is generally milder.
Q: How long until results show? Both peptides show measurable change by week 4–6 in published trial cohorts.
Q: Are these available in the Philippines? Yes — Noki Labs ships nationwide. We strongly recommend consulting a licensed healthcare provider familiar with peptide protocols before starting.
Always consult a licensed healthcare provider before starting any new peptide or wellness regimen. Individual results vary. Statements about our products are educational and not intended to diagnose, treat, cure, or prevent any disease.
Last reviewed: May 2026 · Read more in our FAQ